News & Videos - NOVELION THERAPEUTICS INC.

VANCOUVER, British Columbia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today provides an update on the Company’s voluntary liquidation process (the “Liquidation”) that started on January 16, 2020 (the “Effective Date”). Liquidation Update The Liquidator continues to believe that it will be able to complete a distribution in the fourth...

VANCOUVER, British Columbia, July 08, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) announces that it has ceased to be a reporting issuer under Canadian securities legislation in each of the provinces of Canada as a result of an order issued by the British Columbia Securities Commission on behalf of itself and other Canadian securities regulatory...

VANCOUVER, British Columbia, June 12, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) by Alvarez & Marsal Canada Inc., Novelion’s court appointed liquidator (the “Liquidator”) today provides an update on the Company’s voluntary liquidation process (the “Liquidation”) that started on January 16, 2020 (the “Effective Date”). Liquidation Update The Liquidator is currently administering the Court-approved claims process, the purpose of which...

VANCOUVER, British Columbia, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (“Novelion” or the “Company”) today announced that the implementation of the Company’s voluntary liquidation (the “Liquidation”) commenced at 5:00 p.m. Pacific Time today, January 16, 2020 (the “Effective Date”). As of the Effective Date, Alvarez & Marsal Canada Inc. was appointed liquidator (the “Liquidator”) and charged with overseeing all aspects of the Liquidation. Concurrent with...

VANCOUVER, British Columbia, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced the definitive date for commencement of implementation of the Company’s voluntary liquidation (the “Liquidation”) as 5:00 p.m. Pacific Time on January 16, 2020. Court Orders, Statement of Intent to Liquidate and Definitive Effective Date The Company announced that the Supreme Court of British Columbia (the “Court”) has granted...

VANCOUVER, British Columbia, Jan. 03, 2020 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today provided updates on the status of the Company’s voluntary liquidation and other matters. Background on Company Liquidation As previously announced, at the Company’s 2019 Annual General Meeting held November 5, 2019, shareholders voted in favor of all proposals contained in the Company’s proxy statement dated October 3, 2019 (the “Proxy...

VANCOUVER, British Columbia, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced that a hearing date has not yet been scheduled for consideration of the Company’s application materials, filed on November 18, 2019 with the Supreme Court of British Columbia (the “Court”), relating to Court orders sought by the Company in connection with the Company’s voluntary liquidation and dissolution (the “Liquidation”)....

VANCOUVER, British Columbia, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today provided updates on the status of the Company’s voluntary liquidation and other matters. Background on Company Liquidation As previously announced, at the Company’s 2019 Annual General Meeting held November 5, 2019 (the “Meeting”), shareholders voted in favor of all proposals contained in the Company’s proxy statement dated October 3,...

VANCOUVER, British Columbia, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) today announced the results of its 2019 Annual General Meeting of Shareholders, held on November 5, 2019 (the “Meeting”). A total of 16,617,423 common shares were represented at the Meeting, constituting 84.70% of the Company’s issued and outstanding shares. Shareholders voted in favor of all proposals contained in the Company’s proxy statement...

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (Ticker: NVLNF) (“Novelion” or the “Company”) announced that, effective as of the opening of business today, its common shares have commenced trading under the symbol “NVLNF” on an over-the-counter stock market (the “OTC”). This news follows the October 8, 2019 announcement that the Company’s shares would be delisted and suspended from trading on the Nasdaq Stock...

VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that on October 7, 2019 the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (the “Panel”) has determined to affirm the Listing Qualifications Staff’s (“Staff”) decision to delist the Company’s shares from the Nasdaq Stock Market LLC (“Nasdaq”) and that trading of the...

VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) today announced that it has filed its notice of meeting and definitive proxy statement with the applicable securities regulatory authorities in connection with the proposals to be voted on at the Company’s 2019 annual general meeting of shareholders (the “Annual Meeting”), including the proposed liquidation and dissolution of...

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated September 11, 2019, the acquisition by Amryt Pharma Plc (“Amryt”) of 100% of the outstanding equity interests of Novelion’s reorganized subsidiary, Aegerion Pharmaceuticals, Inc. (“Aegerion”) as contemplated in Aegerion’s First Amended Joint Chapter 11 Plan (the “Amryt...

VANCOUVER, British Columbia, and CAMBRIDGE, Mass., Sept. 11, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 30, 2019, the United States Bankruptcy Court for the Southern District of New York (the “Bankruptcy Court”) entered an order on September 10, 2019 confirming Aegerion’s First Amended Joint Chapter 11 Plan (the “Plan”), as modified to reflect certain resolutions...

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”), announced that, further to its press release dated August 21, 2019, it has received a notice from the Nasdaq Hearings Panel (the “Panel”) granting a 15-calendar day stay, until September 12, 2019, of the delisting of the Company’s common stock from The Nasdaq Stock Market in response to the Company’s request for a hearing....

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 21, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN) (“Novelion” or the “Company”) announced that, further to its press release dated August 12, 2019, the British Columbia Securities Commission and the Ontario Securities Commission (on behalf of the applicable Canadian securities regulatory authorities) have issued a general “failure to file” cease trade order (“CTO”) dated August 20, 2019 in respect of the...

VANCOUVER, British Columbia and CAMBRIDGE, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases (“Novelion” or the “Company”), announced that it has determined that it will be unable to file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2019, including the related management’s discussion and analysis and CEO and CFO...

VANCOUVER, British Columbia, July 16, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on July 16, 2019, the Supreme Court of British Columbia (“BC Court”) issued its decision in response to the previously announced petition filed by Whitefort Capital Master Fund, LP (“Whitefort”) against Novelion, as respondent,...

VANCOUVER, British Columbia, June 24, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare metabolic diseases (“Novelion”), announced that on June 20, 2019, Whitefort Capital Master Fund, LP (“Whitefort”) filed a petition (the “Whitefort Action”) against Novelion Therapeutics Inc. (“Novelion”), as respondent, in the Supreme Court of British Columbia seeking a...

VANCOUVER, British Columbia, and CAMBRIDGE, Mass., May 07, 2019 (GLOBE NEWSWIRE) -- Novelion Therapeutics Inc. (NASDAQ: NVLN), a biopharmaceutical company dedicated to developing and commercializing therapies for individuals living with rare diseases (“Novelion” or the “Company”), today reported financial results for the first quarter ended March 31, 2019. Novelion’s Interim Chief Executive Officer Ben Harshbarger commented, “We continue to execute on our goals of achieving target...